Chamuangone-rich rice bran oil ameliorates neurodegeneration in AlCl₃/D-galactose model via modulation of behavioral, biochemical, and neurochemical parameters

Badriyah S. Alotaibi¹, Uzma Saleem²*, Maryam Farrukh³, Sadaf Waseem³, Zunera Chauhdary³, Ifat Alshari⁴, Wedad Saeed Alqahtani⁵, Abdullah R. Alanzi⁶, Mona N. BinMowyna⁷, Muhammad Ajmal Shah⁸,⁹, Khairul Anam⁹, Yasmene F. Alanazi¹⁰, Abdulelah M. Almuwallad¹¹, Abdulmajid M. Almuwallad¹¹, Pharkphoom Panichayupakaranant¹², Ana Sanches Silva¹³–¹⁵*

¹Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bBint Abdulrahman University, PO. Box 84428, Riyadh 11671, Saudi Arabia; ²Punjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan; ³Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan; ⁴Department of Biology, Jamoum University College, Umm Al-Qura University, Makkah, Saudi Arabia; ⁵King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), MNGHA, Saudi Arabia; ⁶Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; ⁷College of Education, Shaqra University, Shaqra, Saudi Arabia; ⁸Department of Pharmacy, Hazara University, Mansehra, Pakistan; ⁹Department of Pharmacy, Faculty of Medicine, Diponegoro University, Jl. Prof. Mr. Sunario, Tembalang, Semarang, Central Java, Indonesia; ¹⁰Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia; ¹¹Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University Hospital, Jeddah, Saudi Arabia; ¹²Department of Pharmacognosy & Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Thailand; ¹³University of Coimbra, Faculty of Pharmacy, Polo III, Azinhaga de Stª Comba, Coimbra, Portugal; ¹⁴Centre for Animal Science Studies (CECA), ICETA, Porto, Portugal; ¹⁵Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Lisbon, Portugal

*Corresponding Authors: Uzma Saleem, Punjab University College of Pharmacy, University of the Punjab, Lahore 54000, Pakistan. Email: uzma95@gmail.com; Muhammad Ajmal Shah, Department of Pharmacy, Hazara University, Mansehra, Pakistan. Email: ajmalshah@hu.edu.pk; Pharkphoom Panichayupakaranant, Department of Pharmacognosy & Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Thailand. Email: pharkphoom.p@psu.ac.th; Ana Sanches Silva, Faculty of Pharmacy, University of Coimbra, Polo III, Azinhaga de Stª Comba, Coimbra 3000-548, Portugal. Email: asanches.silva@ff.uc.pt

Received: 15 May 2024; Accepted: 3 July 2024; Published: 22 July 2024
© 2024 Codon Publications

Abstract

Chamuangone is an exotic medicinal compound isolated from Garcinia cowa leaves. It shows great potential against inflammation, neurodegeneration, and oxidation. Through green extraction method, chamuangone-rich rice bran oil (CRBO) containing 1.97 mg/mL chamuangone was obtained. This research study investigates the therapeutic effects of CRBO on D-galactose- and aluminum chloride (AlCl₃)-induced Alzheimer's disease in rat model. In all, 30 rats were divided into six groups and treated for 42 days as follows: control group (vehicle), disease control group (AlCl₃ 150 mg/kg + D-galactose 150 mg/kg p.o.), standard group (rivastigmine 3 mg/kg p.o.), and CRBO treatment groups with doses of 2.5, 5.0, and 7.5 mg/kg p.o. Neurobehavioral studies were performed on completion of 42 days. Furthermore, biochemical, neurochemical, and histopathological analyses were performed. CRBO treatment mitigated impairment in neuromuscular coordination, mentation and cognition in behavioral tasks. It potentially recovered (p < 0.001) the declined level of catalase, superoxide dismutase, reduced glutathione and lipid peroxidation. Neurochemical analysis revealed the restoration of serotonin, noradrenaline, and dopamine concentration in the brain after CRBO treatment. Histopathological examination of vital organs revealed recovery in CRBO-treated rats in a dose-dependent manner. Owing to neurotoxic effects of inducing
agents, the level of acetylcholinesterase decreased in disease control group; however, CRBO treatment recovered the declined activity of this enzyme. Therefore, it is concluded that CRBO significantly recovered the neurodegenerative effects through multiple pathways, such as amelioration of oxidative stress and neuronal plasticity. Therefore, this innovative green remedy can be considered as a natural alternative for treating neurodegenerative disorders.

**Keywords:** Alzheimer’s disease; animal behavior; chamuangone-rich rice bran oil, neurochemical analysis; neuro-inflammation, phytomedicine

---

**Introduction**

Loss of neurons in motor, sensory, or cognitive regions of the brain is usually selective and symmetrical in many neurodegenerative disorders. They are characterized by cell loss patterns and the discovery of cellular markers specific to diseases (Martin, 1999). The most prevalent form of dementia that develops in mid-to-late life is Alzheimer’s disease (AD), a complicated and profoundly diverse medical condition (Sisodia, 1999). Approximately 5 million new cases of dementia are discovered every year, affecting over 24 million individuals worldwide, the majority of whom have AD (Qiu et al., 2022). The earliest stage in AD is mild, and there are no clear indications that could make way for a timely diagnosis prior to irreversible abnormalities (Förstl and Kurz, 1999). Decline in cognition, diminished routine tasks of everyday life, and accompanying behavioral problems are manifested at early stages (Shin et al., 2005). In moderate to mild conditions, severe depression is linked with apathy, difficulty in sleeping, negative mood, feelings of low self-worth, nervousness, and despair. In severe condition, likelihood of reduced severe depression is observed, while agitation, psychosis, and aggression are increased (Lopez et al., 2003).

Alzheimer’s disease is an age-related neurodegenerative condition described clinically by an ongoing decrease in cognitive capacity whereas formation of senile plaques, neurofibrillary tangles (NFTs), and neuronal degeneration in specific brain areas is the pathological explanation (Kim and Tsai, 2009). Cortex, entorhinal cortex (EC), hippocampus, ventral striatum, and cerebral cortex of the brain are the most affected parts (Hampel et al., 2018). Reduced cholinergic activity in the brain of AD patients is prevalent whereas experimental research has demonstrated that acetylcholinesterase (AchE) has a vital role in learning and memory (Craig-Schapiro et al., 2009). The basal forebrain complex’s cholinergic neurons are described to suffer moderate degenerative alterations with aging. This results in cholinergic hypofunction, linked to the progression of memory problems with aging, causing observed deficits in cognition, thus contributing to the formation of cholinergic theories of memory dysfunction in geriatrics, leading to the formation of β-amyloid plaques (Schliebs and Arendt, 2006). Autophagy and mitochondrial dysfunction are initial and most promising factors in AD pathogenesis. Incomplete autophagy procedure imparts too many degraded macromolecules, which deposit in the brain and affects brain functioning (Tran and Reddy, 2021). Malfunctioning of mitochondria causes synapses to build up lipofuscin, which may worsen neuronal dysfunction (Moreira et al., 2010).

Another main phenomenon in the pathophysiology of AD is oxidative stress, since the brain is more susceptible to oxidative stress than other organs. Most neuronal components (lipids, proteins, and nucleic acids) tend to be oxidized in AD due to mitochondrial malfunction, elevated metal levels, inflammation, and β-amyloid (Aβ) peptides (Chen and Zhong, 2014). AchE inhibitors are first-line treatment for AD and are linked to improve cognitive function, behavior, and activities of daily living. Memantine can also be used in combination with AchE inhibitors (Winslow et al., 2011). Second-generation (atypical) antipsychotic medications are also frequently used for treating psychosis, aggression, and agitation in AD patients (Caraci et al., 2020; Schliebs and Arendt, 2006). The ‘disease-modifying’ medications, having capability to treat AD at initial stages, are researched actively. To halt disease progression, these medications must delay pathological phases which trigger clinical symptoms, such as the formation of extracellular amyloid plaques and intracellular NFTs, inflammatory conditions, oxidative damage, iron deregulation, and cholesterol metabolism (Yiannopoulou and Papageorgiou, 2013). Herbal medicines have been used since ancient times to treat behavioral and psychological AD symptoms with varying degrees of success and fewer adverse effects. Although some US Food and Drug Administration (FDA)-approved therapies are available for managing AD, the results tend to be insufficient; thus herbal therapies have a significant role in treating AD (Jadhav et al., 2019).

D-galactose, a brain sugar, is a source of energy for various processes. Recent studies have shown that certain diseases, such as AD, are induced by D-galactose
because it causes abnormal alterations in mitochondrial cells, along with the formation of oxidative free radicals, damaging neurons and causing dementia in experimental animals (Hua et al., 2007). Aluminum chloride is also demonstrated to form twisted tangles resulting in AD (Kumar and Singh, 2015).

‘Chamuang’ is a Thai name of *Garcinia cowa*. It is an edible plant of the Clusiaceae family. This plant is a small to medium size tree of 30-m height. Its fruits having a nasty taste are consumed (Yorsin et al., 2023). Parts of *Garcinia cowa* have many medicinal benefits. Many pharmacological attributes related to this plant are reported, such as antiviral, antidepressant, antifungal, antioxidant, anti-leishmaniasis, antitumor, and anti-obesity properties. In many parts of the world, *Garcinia cowa* is used traditionally for improving blood circulation, as an expectorant, and for indigestion. Phloroglucinols, chamuangone, xanthones, cowaxanthone, flavonoids, and garcicowanone are the main phytoconstituents of the plant (Panichayupakaranant and Sakunpak, 2013). Polyoxygenated xanthones and garcicowanone manifested strong neuroprotective and antioxidant potential by inhibiting the synthesis of reactive oxygen species and reducing Ca$^{2+}$ influx (Tran et al., 2022).

Chamuangone manifested a potentially strong chemotherapeutic activity by constraining cell proliferation and prompting apoptosis in HeLa cell lines (Sae-Lim et al., 2020); it also showed cytotoxic effects against lung leukemia and adenocarcinoma cell lines (Sakunpak et al., 2017). Studies have demonstrated a substantial antibacterial property of active component chamuangone (Sakunpak and Panichayupakaranant, 2012). Using a green microwave-aided extraction method, chamuangone-rich rice bran oil (CRBO) was produced. It demonstrated strong anticancer activity against human cancer cell lines and was noninvasive to normal cells (Sae-Lim et al., 2019b). In light of recently reported pharmacological activities of chamuangone (Alotaibi et al., 2024), this study was planned to explore the neuroprotective potential of CRBO against D-galactose- and aluminum chloride-induced Alzheimer’s rat model.

**Materials and Methods**

**Provenance of chamuangone-rich rice bran oil**

Green microwave-assisted extraction method was used to prepare standardized CRBO. The standardization was carried out by high-performance liquid chromatography (HPLC; 1.97 mg/mL) at Phytomedicine and Pharmaceutical Biotechnology Excellence Centre, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand (Sae-Lim et al., 2019a).

**Animal husbandry**

The experiment was conducted on 30 rats of either gender weighing 100–200 g. The rats were purchased from the animal house of Government College University, Faisalabad. They were kept in close supervision under ideal conditions (room temperature: 22 ± 3°C, humidity: 30–55%, and a 12-h dark and light cycle) for about 7 days prior to beginning the experiment to make animals sufficiently relaxed.

**Study design**

Six groups of mice were created (n = 5). Group 1 was the control group that received vehicle only. Group 2 was the disease control group that was administered aluminum chloride and D-galactose orally 150 mg/kg each. Group 3 was the standard group and administered 3 mg kg of oral rivastigmine. Groups 4–6 were CRBO-treated groups with CRBO oral doses of 2.5, 5.0, and 7.5 mg/kg. Behavioral changes in animals were studied by taking neurobehavioral observations on day 42 of the study. Blood was collected with the help of cardiac puncture for biochemical and hematological analyses. The animals were anesthetized by using 10% isoflurane. The brain, heart, kidney, liver, and lungs were excised by cervical dislocation for histopathological analysis. All vital organs were preserved in 10% formalin, while brain tissues were kept in ice-cold phosphate buffer for measuring neurotransmitters.

**Neurobehavioral observations (Table S1)**

**Open field test**

Different behaviors, such as movement and mental state of animals, were assessed with the help of open field test by measuring locomotion. The setup contained a square box having a field (60 × 60 cm) containing 36 squares (10 × 10 cm) enclosed by a wall of Plexiglas having 25-cm height. Of these 36 squares, 20 squares that were close to the wall was named ‘peripheral field’ and the rest of 16 squares was named ‘closed field’ squares. The animals were placed on a quadrant to discover field. Number of lines crossed, motility, scratching, and peripheral exploration were observed with the help of a camera (Chauhdary et al., 2019).

**Morris water maze test**

This is a dimensional comprehension trial that requires navigating from points of origin along the shore of an unrestricted aquatic area to a hidden evacuation station employing peripheral stimuli (Vorhees and Williams, 2006). The apparatus for this test comprised a pool of water having a diameter of 1.5–2.0 m. The water was
treated with a substance that changed its appearance into an easily noticeable form. An escape object was placed in hiding sufficiently from the water surface to test the attributes related to the animal’s motivation to escape, such as the distance covered and the swimming speed to reach upwards. The findings of this test established the spatial and temporal ability of animals (Nunez, 2008).

Y-maze test
Animals’ short-term spatial memory was assessed using the Y-maze test as a means of recognizing. The apparatus constructed of plywood comprised of three arms. The length, height, and width of the arms were 50 cm, 32 cm, and 16 cm, respectively, and they crossed each other at an angle of 120°. After 1 h of the last dose, the rat was positioned near one of the arms and had the freedom to roam around the maze for about 10 min. Total count of entries using all four paws inside every arm were observed and noted properly. Spontaneous repetitions were determined as they manifested short-term memory and degree of arm entries without repetition, and this is also called alternation rate (Ghafouri et al., 2016).

\[
\text{Spontaneous alterations} = \text{Total number of arms entered} - 2
\]

\[
\text{Alternation percentage} = \frac{\Delta \text{Actual alternation}}{\text{Actual alternation}} \times 100
\]

Elevated maze test
This experiment was carried out to determine reminiscence, anxiety-like behavior as well as the learning ability of rodents. The maze designed for performance had four arms, each of 50 cm length and 10 cm breadth; two of the arms were open without walls, and remaining two were confined to 30-cm high walls. It was built of moderately dense board made up of fiber and has a dark surface. Each maze arm was hooked to robust plastic legs, elevating it 50 cm above the foundation (Walf and Frye, 2007). All the arms were visible to animals, and they were able to roam freely within them. On 38th day, after 60 min of drug administration, each animal was positioned at open arm of elevated maze. The time taken in each arm, total number, and movement from open into close arm were observed for 90 s. On 42nd day, after 24 h, the same practice was repeated to determine memory retention (Komada et al., 2008).

Quantification of oxidative stress biomarkers
Levels of glutathione peroxidase (GPx), superoxide dismutase (SOD), lipid peroxidation, catalase, total protein contents, and reduced glutathione (GSH) were measured using brain homogenates.

Preparation of brain homogenate
Brain homogenate was prepared using 0.1-molar phosphate buffer with the help of a homogenizer. The homogenate had undergone centrifugation at 4000 rpm at a temperature of 4°C and the supernatant layer was separated, which was utilized for testing (Saleem et al., 2022).

Measurement of malondialdehyde (MDA)
Approximately 3 mL of 0.38% thiobarbituric acid was added to 1 mL of aliquots of buoyant and stirred. After cooling in an ice bath, the mixture was centrifuged for 10 min at 3500 rpm and incubated of 15 min. The top layer was assessed by a 532-nm absorbance measurement (Ayaz et al., 2022) by the following equation:

\[
\text{Concentration of MDA} = \frac{\text{Abs} \times 100 \times \text{Vt}}{(1.56 \times 105) \times \text{weight of tissue} \times \text{Vu}}.
\]

where:

- \(\text{Abs} = \) absorption of sample at 532 nm;
- \(\text{Vt} = \) complete volume of mixture;
- \(\text{Vu} = \) aliquot volume.

Measurement of catalase activity
In order to measure the level of catalase, 0.05 mL of separated brain homogenate solution, 1.95 mL of 50-mM phosphate buffer, and 1 mL 30-mM hydrogen peroxide (H\(_2\)O\(_2\)) were combined to create a 3-mL mixture. Absorbance variations were noted at 240 nm. The coefficient of extinction of oxidized H\(_2\)O\(_2\) in millimoles (mM) was calculated. The catalase activity (CAT) was measured in the form of \(\mu\text{mol/min/mg of proteins}\) (Fatima et al., 2022) by the following equation:

\[
\text{CAT} = \frac{\delta \text{O.D}}{E \times \text{Volume sample (mL)} \times \text{Protiens (mg)}}
\]

where:

- \(\delta \text{O.D} = \) minute changes in absorbance;
- \(E = \) coefficient of extinction of H\(_2\)O\(_2\) in mM.

Measurement of glutathione
Glutathione level was determined by mixing homogenized tissue (1 mL) with 10% trichloroacetic acid (TCA, 1 mL) prior to be used to assay GSH. In order to calculate absorbance at 412 nm, reagent 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB, 0.5 mL) was combined with
a fraction of supernatant and phosphate solution (4 mL) (Bais et al., 2015):

\[
GSH = \frac{Y - 0.00314}{0.0314 \times Vi \times T \times Vu}
\]

where:
Y = absorption of the sample;
D\(f\) = diluting agent (1);
T = homogenate of tissue.
Vu = Quantity of the aliquot

Measurement of superoxide dismutase

A mixture of 1.2 mL of sodium phosphate buffer having 7.4 pH, 100-mL brain homogenate, 100-mL phenazine methosulfate (186 mM), about 200-mL triton X, 300 mL of nitro blue tetrazolium (300 mM) was formulated. The mixture was allowed to incubate at 30°C for about 95 s. The reaction process was halted by adding glacial acetic acid following the addition of 4 mL of n-butanol and settling it for about 10 min for isolation of n-butanol layer; which was centrifuged at 1000 rpm. Absorbance was recorded at 560 nm (Kim et al., 2016).

Measurement of protein level

Two types of reagents were prepared to measure protein levels. Reagent 1 contained 1 mL of 0.5% copper sulfate and 2% sodium carbonate (Na\(_2\)CO\(_3\); 48 mL) in 0.1-N NaOH. It also contained 1% sodium potassium tartrate (1 mL) in distilled water. This reagent was taken in a test tube along with brain homogenate and kept for about 10 min. The second reagent was prepared by taking 1 part of water and 2 parts of 0.5-mL folin phenol (2 N). Both reagents were mixed together and incubated for around 30 min with 37°C. The absorbance was recorded at 660 nm. The regression line was designed by taking different concentrations of bovine serum albumin (BSA) (Lowry et al., 1951).

Quantification of neurotransmitters

Aqueous phase formulation

A tissue specimen was prepared and centrifuged at 2000 rpm for 10 min with 5 mL of hydrochloric acid and butanol. After separating the upper layer, it was added to a sample tube along with 0.1-M HCL (0.31 mL) and heptane (2.5 mL). Following vigorous shaking, the mixture was left for 10 min and again centrifuged for 10 min at 2000 rpm. Two layers were formed: the upper one was decanted to test the level of neurotransmitters (Saleem et al., 2022).

Measurement of serotonin level

Aqueous phase of 0.2 mL was mixed with 0.25 mL of o-phthalialdehyde (OPT). Then for about 10 min, this mixture was heated to a temperature of 100°C and cooled to room temperature. Absorbance was determined at 440 nm (Saleem et al., 2021).

Measurement of acetylcholinesterase

Acetylthiocholine iodide (20 µL), 2,4-dithiobis nitrobenzoic acid (100 µL), and phosphate buffer (2.6 mL; pH 8.00, 0.1 M) were combined. Brain homogenate (0.4 mL) was added to this mixture. The 2,4-dithiobisnitrobenzoic acid and thiocholine reaction developed a yellow color. At the end, absorbance was measured at 412 nm (Saleem et al., 2020):

\[
R = 5.74 \times 10^{-4} \times \frac{A}{CO}
\]

where:
CO = actual quantity of tissues (mg/mL);
\(A\) = difference in absorbance per minute;
R = Speed of substrate hydrolysis per gram of tissue.

Measurement of noradrenaline and dopamine

Mixture of 0.4-M hydrochloric acid (0.05 mL), aqueous phase (0.2 mL), and sodium acetate buffer (0.1 mL) was formulated. Sodium sulphite (0.1 mL) was added to precede the process of oxidation. After about 90 s, 0.1-mL acetic acid and 100-µL Na\(_2\)SO\(_3\) were added to the reaction mixture to stop oxidation process. This was then exposed to heating at 100°C for 5 min before cooling off. Then the absorption was measured at 359 nm and 450 nm (Saleem et al., 2022).

Histopathological analysis of brain and vital organs

The rats were anesthetized with 10% isoflurane and slaughtered by cervical dislocation. Brain and all vital organs were removed and each organ was weighed accordingly. All vital organs were stored in 10% formalin solution, while the brain was retained in an ice-cold phosphate buffer (pH 7.4). The slides were prepared with hematoxylin and eosin (H&E) staining, and photographic images were captured at 40× resolution with the help of optical microscopic.

Statistical considerations

The numerical findings of the study were presented as mean ± standard error of mean (SEM). The results were statistically evaluated (by version 5 of Graph Pad Prism) by applying one-way ANOVA along with Bonferroni post-test and two-way ANOVA tailed by Tukey test; \(p < 0.05\) was considered as statistically significant.
Results and Discussion

Behavioral observations

Open field test
The 2.5-, 5.0-, and 7.5-mg/kg CRBO-treated groups showed remarkable \( (p < 0.001) \) elevation in the physical activity of animals. The disease control group manifested a remarkable \( (p < 0.001) \) decrease in movement, compared to the control group (Figures 1–3).

Morris water maze test
On day 42, escape latency (EL) was measured for acquisition test. The disease control group displayed a substantial \( (p < 0.001) \) increase in comparison to the control group. Treatment groups with different doses of CRBO showed a remarkable \( (p < 0.001) \) fall in escape latency values, compared to the disease control group (Figure 4 and Table 1).

Y-maze test
The number of alterations, arm entries, and triads were measured. The disease control group manifested a remarkable \( (p < 0.001) \) drop in the entries compared to

---

**Figure 1.** Effect of chamuangone-rich rice bran oil on experimental rats observing square crossing in open field test. Mean ± SEM (n = 5) is applied to quantify the results. \( ^*p < 0.05, ^{**}p < 0.01, \) and \( ^{***}p < 0.001 \) compared to the control group. \( *p < 0.05, **p < 0.01, \) and \( ***p < 0.001 \), compared to the disease control group.

**Figure 2.** Effect of chamuangone-rich rice bran oil on experimental rats observing peripheral exploration in open field test. Mean ± SEM (n = 5) is applied to quantify the results. \( ^*p < 0.05, ^{**}p < 0.01, \) and \( ^{***}p < 0.001 \), compared to the control group. \( *p < 0.05, **p < 0.01, \) and \( ***p < 0.001 \), compared to the disease control group.

**Figure 3.** Effect of chamuangone-rich rice bran oil on experimental rats observing central exploration in open field test. Mean ± SEM (n = 5) is applied to quantify the results. \( ^*p < 0.05, ^{**}p < 0.01, \) and \( ^{***}p < 0.001 \), compared to the control group. \( *p < 0.05, **p < 0.01, \) and \( ***p < 0.001 \), compared to the disease control group.

**Figure 4.** Effect of chamuangone-rich rice bran oil on escape latency in Morris water maze test. Mean ± SEM (n = 6) is applied to quantify the results. \( ^*p < 0.05, ^{**}p < 0.01, \) and \( ^{***}p < 0.001 \), compared to the control group. \( *p < 0.05, **p < 0.01, \) and \( ***p < 0.001 \), compared to the disease control group.
the control group. The dose-dependent CRBO treatment groups showed a remarkable \((p < 0.001)\) dose-dependent improvement in alterations, triads, and entries (Figures 5–7).

### Elevated maze test

On day 42 of the study, transfer latency was examined to ascertain animals' cognitive nature, which displayed a substantial \((p < 0.001)\) increase in disease control, compared to the control group. Dose-dependent CRBO treatment groups showed a remarkable \((p < 0.001)\) loss in transfer latency, compared to the standard group (Figure 8).

### Biochemical Testing

The disease control group presented a substantial \((p < 0.001)\) decrease in the levels of CAT, SOD, and GSH activity in comparison to the control group. The standard (rivastigmine) treatment group exhibited a remarkable \((p < 0.001)\) elevation in these oxidative biomarkers, compared to the disease control group. Dose-dependent increase in the concentrations of CAT, SOD, and GSH were observed whereas the disease control

---

**Table 1. Effect of chamuangone-rich rice bran oil on all quadrants of time latency in Morris's water maze test.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Dose (mg/kg)</th>
<th>North quadrant</th>
<th>South quadrant</th>
<th>East quadrant</th>
<th>West quadrant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease control (AlCl(_3) + D galactose)</td>
<td>150 + 150</td>
<td>24.7 ± 0.57</td>
<td>13.6 ± 0.64</td>
<td>16.3 ± 0.52</td>
<td>17.3 ± 0.68</td>
</tr>
<tr>
<td>Standard (rivastigmine)</td>
<td>3</td>
<td>42.0 ± 0.68(^{**})</td>
<td>37.0 ± 0.97(^{***})</td>
<td>38.5 ± 0.80(^{***})</td>
<td>52.5 ± 0.80(^{***})</td>
</tr>
<tr>
<td>Treatment groups</td>
<td>2.5</td>
<td>14.0 ± 0.57(^{*})</td>
<td>23.9 ± 0.06(^{***})</td>
<td>17.1 ± 0.55(^{***})</td>
<td>23.0 ± 0.80(^{***})</td>
</tr>
<tr>
<td></td>
<td>5.0</td>
<td>29.0 ± 0.57(^{***})</td>
<td>40.0 ± 0.57(^{**})</td>
<td>33.0 ± 0.55(^{***})</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.5</td>
<td>37.0 ± 0.57(^{*})</td>
<td>38.3 ± 0.58**</td>
<td>30.2 ± 0.58**</td>
<td>32.0 ± 0.58**</td>
</tr>
</tbody>
</table>

Mean ± SEM \((n = 6)\) is applied to quantify the results. \(^{#}p < 0.05, \(^{##}p < 0.01, \(^{###}p < 0.001,\) compared to the control group. \(^{*}p < 0.05, \(^{**}p < 0.01, \(^{***}p < 0.001,\) compared to the disease control group.

---

**Figure 5. Effect of chamuangone-rich rice bran oil on experimental rats observing number of triads in Y-maze test.** Mean ± SEM \((n = 5)\) is applied to quantify the results. \(^{#}p < 0.05, \(^{##}p < 0.01, \(^{###}p < 0.001,\) compared to the control group. \(^{*}p < 0.05, \(^{**}p < 0.01, \(^{***}p < 0.001,\) compared to the disease control group.

**Figure 6. Effect of chamuangone-rich rice bran oil on experimental rats observing number of arm entries in Y-maze test.** Mean ± SEM \((n = 5)\) is applied to quantify the results. \(^{#}p < 0.05, \(^{##}p < 0.01, \(^{###}p < 0.001,\) compared to the control group. \(^{*}p < 0.05, \(^{**}p < 0.01, \(^{***}p < 0.001,\) compared to the disease control group.

**Figure 7. Effect of chamuangone-rich rice bran oil on experimental rats observing spontaneous alterations in Y-maze test.** Mean ± SEM \((n = 5)\) is applied to quantify the results. \(^{#}p < 0.05, \(^{##}p < 0.01, \(^{###}p < 0.001,\) compared to the control group. \(^{*}p < 0.05, \(^{**}p < 0.01, \(^{***}p < 0.001,\) compared to the disease control group.
Chamuangone-rich rice bran oil for treating neurodegenerative disorders

Figure 8. Effect of chamuangone-rich rice bran oil on experimental rats observing transfer latency in elevated maze test. Mean ± SEM (n = 5) is applied to quantify the results. *p < 0.05, **p < 0.01, and ***p < 0.001, compared to the control group. †p < 0.05, ‡p < 0.01, and §§p < 0.001, compared to the disease control group.

Quantification of Neurotransmitters

Measurement of acetylcholinesterase
Acetylcholinesterase was remarkably (p < 0.001) elevated in the disease control group in comparison to the control group. Significant (p < 0.001) decrease in enzyme levels was observed, being the lowest at 7.5 mg/kg of CRBO as compared to 2.5, 5.0 mg/kg and the standard (Figure 9).

Measurement of serotonin, dopamine, and noradrenaline
Levels of serotonin, dopamine, and noradrenaline declined remarkably (p < 0.001) in the disease control group, compared to the control group. CRBO-treated mice displayed a significant (p < 0.001) increase at 2.5, 5.0, and 7.5 mg/kg in the levels of these neurotransmitters as compared to the disease control group (Tables 3–5).

Figure 9. Effect of chamuangone-rich rice bran oil on AChE activity. Mean ± SEM (n = 6) is applied to quantify the results. *p < 0.05, **p < 0.01, and ***p < 0.001, compared to the control group. †p < 0.05, ‡p < 0.01, and §§p < 0.001, compared to the disease control group.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Dose (mg/kg)</th>
<th>AChE (µmol/mg of brain tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td>0.9 ± 0.01</td>
</tr>
<tr>
<td>Disease Control</td>
<td></td>
<td>1.9 ± 0.01</td>
</tr>
<tr>
<td>Standard</td>
<td>2.0 ± 0.01</td>
<td>3.4 ± 0.01</td>
</tr>
<tr>
<td>2.5 mg/kg</td>
<td>1.9 ± 0.01</td>
<td>3.0 ± 0.01</td>
</tr>
<tr>
<td>5 mg/kg</td>
<td>1.4 ± 0.02</td>
<td>2.1 ± 0.02</td>
</tr>
<tr>
<td>7.5 mg/kg</td>
<td>1.3 ± 0.02</td>
<td>3.5 ± 0.06</td>
</tr>
</tbody>
</table>

Table 2. Effect of chamuangone-rich rice bran oil on biochemical markers in brain homogenate.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Dose (mg/kg)</th>
<th>Catalase (mmol/mg)</th>
<th>Superoxide dismutase (µg/mg of proteins)</th>
<th>Malondialdehyde (µmol/mg of proteins)</th>
<th>Reduced glutathione (µg/mg of proteins)</th>
<th>Glutathione peroxidase (µg/mg of proteins)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td>3.8 ± 0.06</td>
<td>1.4 ± 0.02</td>
<td>7.9 ± 0.06</td>
<td>0.8 ± 0.02</td>
<td>7.6 ± 0.06</td>
</tr>
<tr>
<td>Disease Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>3.4 ± 0.17</td>
<td>1.9 ± 0.06</td>
<td>6.2 ± 0.02</td>
<td>7.8 ± 0.04</td>
<td>0.9 ± 0.01</td>
<td>8.3 ± 0.02</td>
</tr>
<tr>
<td>2.5 mg/kg</td>
<td>3.1 ± 0.01</td>
<td>1.9 ± 0.06</td>
<td>6.2 ± 0.02</td>
<td>7.8 ± 0.04</td>
<td>0.9 ± 0.01</td>
<td>8.3 ± 0.02</td>
</tr>
<tr>
<td>5 mg/kg</td>
<td>3.3 ± 0.02</td>
<td>1.4 ± 0.04</td>
<td>6.1 ± 0.21</td>
<td>8.4 ± 0.01</td>
<td>0.4 ± 0.05</td>
<td>8.4 ± 0.01</td>
</tr>
<tr>
<td>7.5 mg/kg</td>
<td>3.5 ± 0.06</td>
<td>1.5 ± 0.01</td>
<td>5.8 ± 0.06</td>
<td>9.1 ± 0.06</td>
<td>0.3 ± 0.02</td>
<td>9.1 ± 0.06</td>
</tr>
</tbody>
</table>

SOD: superoxide dismutase; CAT: catalase activity; MDA: malondialdehyde; GSH: glutathione; GPx: glutathione peroxidase.
Table 3. Measurement of serotonin levels in brain homogenate.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Dose (mg/kg)</th>
<th>Serotonin (µg/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>–</td>
<td>0.90 ± 0.006</td>
</tr>
<tr>
<td>Disease control (AlCl₃ + D-galactose)</td>
<td>150 + 150</td>
<td>0.30 ± 0.04**</td>
</tr>
<tr>
<td>Standard (rivastigmine)</td>
<td>3</td>
<td>0.87 ± 0.006***</td>
</tr>
<tr>
<td>Treatment groups</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>0.62 ± 0.11***</td>
</tr>
<tr>
<td></td>
<td>5.0</td>
<td>0.68 ± 0.006***</td>
</tr>
<tr>
<td></td>
<td>7.5</td>
<td>0.72 ± 0.02***</td>
</tr>
</tbody>
</table>

Mean ± SEM (n = 6) is applied to quantify the results. *p < 0.05, **p < 0.01, and ***p < 0.001 differed from the control group. *p < 0.05, **p < 0.01, and ***p < 0.001 differed from the disease control group.

Table 4. Measurement of dopamine levels in brain homogenate.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Dose (mg/kg)</th>
<th>Dopamine (µg/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>–</td>
<td>0.7 ± 0.006</td>
</tr>
<tr>
<td>Disease control (AlCl₃ + D-galactose)</td>
<td>150 + 150</td>
<td>0.3 ± 0.11**</td>
</tr>
<tr>
<td>Standard (rivastigmine)</td>
<td>3</td>
<td>0.7 ± 0.01***</td>
</tr>
<tr>
<td>Treatment groups</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>0.3 ± 0.04***</td>
</tr>
<tr>
<td>Control</td>
<td>5.0</td>
<td>0.4 ± 0.21***</td>
</tr>
<tr>
<td>Disease control (AlCl₃ + D-galactose)</td>
<td>7.5</td>
<td>0.5 ± 0.03***</td>
</tr>
</tbody>
</table>

Mean ± SEM (n = 6) is applied to quantify the results. *p < 0.05, **p < 0.01, and ***p < 0.001 differed from the control group. *p < 0.05, **p < 0.01, and ***p < 0.001 differed from the disease control group.

Table 5. Measurement of noradrenaline levels in brain homogenate.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Dose (mg/kg)</th>
<th>Noradrenaline (µg/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>–</td>
<td>0.7 ± 0.05</td>
</tr>
<tr>
<td>Disease control (AlCl₃ + D-galactose)</td>
<td>150 + 150</td>
<td>0.3 ± 0.04**</td>
</tr>
<tr>
<td>Standard (rivastigmine)</td>
<td>3</td>
<td>0.7 ± 0.05***</td>
</tr>
<tr>
<td>Treatment groups</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>0.3 ± 0.06**</td>
</tr>
<tr>
<td></td>
<td>5.0</td>
<td>0.4 ± 0.01*</td>
</tr>
<tr>
<td></td>
<td>7.5</td>
<td>0.5 ± 0.03***</td>
</tr>
</tbody>
</table>

Mean ± SEM (n = 6) is applied to quantify the results. *p < 0.05, **p < 0.01, and ***p < 0.001 differed from the control group. *p < 0.05, **p < 0.01, and ***p < 0.001 differed from the disease control group.

Measurement of protein level

There was a remarkable decrease (p < 0.001) in protein levels in the disease control group, compared to the control group. Substantial (p < 0.001) elevation in protein levels were discovered when treated with dose-dependent CRBO. Mean value at a dose of 7.5-mg/kg CRBO was 69 ± 0.57 whereas the standard dose showed a mean value of 60 ± 0.68, both values showed mutual resemblance (Table 6).

Examination of histopathology of brain and vital organs

Histopathological examination of brain

The control group had normal brain tissue patterns; on the other hand, the disease control group had evidences of neurodegeneration, such as necrosis, origination of plaques, NFTs, and loss of neurons along with vacuolization. CRBO-treated groups showed dose-dependent restoration in neuronal cells and recovery of NFTs, senile plaques, and vacuolization. The standard group showed resemblance to the control group (Figure 10).

Histopathological analysis of vital organs

Treatment with CRBO did not produce any noticeable toxicity to vital organs. The histology of heart tissues displayed normal myocardial fibers in the groups treated with CRBO, resembling normal heart tissues of the control group. Nevertheless, minor vascular congestion was observed in the disease control group animals, differed from the control group (Figure 11). The disease control group revealed congestion in the renal parenchyma and nuclei whereas CRBO treatment did not cause any abnormality in renal tissues (Figure 12). Figure 13 shows that liver cells (hepatocytes) contained sinusoids that formed a linkage starting from the hepatic artery, reaching the central portal vein. In CRBO-treated groups, normal hepatocytes were observed, resembling the control group without any fibrosis. In the disease control group, the hepatocytes exhibited congestion, vacuolization, and fibrosis, compared to the control group. In both control and standard groups, lung tissues displayed normal epithelium, bronchioles, and pulmonary alveoli. Treatment...
Chamuangone-rich rice bran oil for treating neurodegenerative disorders

Figure 10. Effect of chamuangone-rich rice bran oil on the brain histology of mice. A: brain, 1: control; 2: disease control; 3: standard; 4: 2.5 mg/kg; 5: 5.0 mg/kg; 6: 7.5 mg/kg. SC: satellite cells; SP: senile plaques; V: vacuolization; BA: beta amyloid; OD: oligodenrites; NFTs: neurofibrillary tangles.

Figure 11. Effect of chamuangone-rich rice bran oil on the heart histology of mice. 1: control; 2: disease control; 3: standard; 4: 2.5 mg/kg; 5: 5.0 mg/kg; 6: 7.5 mg/kg. B: heart; CN: central nuclei; MF: myocardial fibrils; ICD: intercalated discs.
Figure 12. Effect of chamuangone-rich rice bran oil on the kidney histology of mice. 1: control; 2: disease control; 3: standard; 4: 2.5 mg/kg; 5: 5.0 mg/kg; 6: 7.5 mg/kg. C: kidney; PCT: proximal convoluted tubule; DCT: distal convoluted tubule; G: glomerulus; P: podocytes; BC: Bowman’s capsule.

Figure 13. Effect of chamuangone-rich rice bran oil on the liver histology of mice. 1: control; 2: disease control; 3: standard; 4: 2.5 mg/kg; 5: 5.0 mg/kg; 6: 7.5 mg/kg. D: liver; CV: central vein; S: sinusoid; HV: hepatic vein; H: hepatocytes; BD: bile duct.
Chamuangone-rich rice bran oil for treating neurodegenerative disorders

Progressive degeneration of certain vulnerable groups of neurons is a characteristic of neurodegenerative disorders such as AD (Dugger and Dickson, 2017). AD is a brain disease caused by neurodegenerative conditions, such as changes in cognition, behavior, and function (Cerquera-Jaramillo et al., 2018). Preclinical AD affects almost eight times more people, compared to symptomatic AD, eventually putting them at a risk of the illness (Cummings et al., 2018). Age and genetics are the risk factors that cannot be avoided. The most defining aspect of AD is memory impairment, which first affects recent episodic memory with progression of the disease. Atypical cases, however, may appear with no amnestic ailment, such as predominance of language, visuospatial working memory, or executive function abnormalities, which commonly affect individuals aged <65 years (Ulep et al., 2018).

The World Health Assembly (WHA), the decision-making body of World Health Organization (WHO), has adopted global strategy for society’s health response to AD; it calls for increased recognition, exploration, and new techniques to address this critical medical problem (Javaid et al., 2021). Over 122,000 individuals died from AD in 2018, a 146% increase from 2000.

Alzheimer’s disease is very expensive for the society, with significant costs associated with medical treatment and caretaking (Piovesan et al., 2023). The clinical manifestations of AD are somewhat alleviated by AchE inhibitors and NMDA antagonists; however, currently no medication is available with a substantial disease-altering effects (Citron, 2004). Clinical trials of combined AD treatments are in progress, focusing on four primary domains: neurodegeneration, cognitive dysfunction, alleged neuroregeneration, and manifestations that are not related to cognition. Targeting of noncognitive manifestations in AD patients is practiced using both herbal and pharmacological therapies (Nagata et al., 2022).

Investigation of AD has resulted in the identification of numerous targets, including all types of histamines, serotonin, cholinergic, monoamine oxidase inhibitors, glycogen synthase kinase-3 (GSK-3), and N-methyl-D-aspartate receptors (NMDAR) that affect the development and aggravation of the illness. Based on these targets, many potent and efficacious therapies for the treatment of AD have been discovered. However, only donepezil, galantamine, rivastigmine, and memantine have received the FDA approval for AD treatment. They are all single-target drugs that may significantly boost

Figure 14. Effect of chamuangone-rich rice bran oil on the lung histology of mice. 1: control; 2: disease control; 3: standard; 4: 2.5 mg/kg; 5: 5.0 mg/kg; 6: 7.5 mg/kg. E: lungs; CE: columnar epithelium; BV: blood vessels; PA: pulmonary alveoli; AS: alveolar sac.
patients’ loss of memory and cognitive decline, but they cannot completely reverse the condition (Yiannopoulou and Papageorgiou, 2020).

Reactive oxygen species (ROS) produced within cells cause neurodegeneration, which is featured by malfunctioning or neuronal death. Acute brain injury is also a common cause. Cysteine/glutamate antipporter system performs poorly if excessive amount of glutamate is present, with production of ROS and depletion of glutathione levels. A cellular oxidative stress causes the mitochondria to fail and opens door for caspase independent apoptosis pathway (Nguyen et al., 2022).

Dementia may be prevented by other ways than using drugs, such as nutritional therapy and lifestyle changes, that are effective in a number of metabolic diseases associated with aging, such diabetes, cardiovascular disease (CVD), obesity, and cancer. These non-pharmacological therapies could be helpful at slowing down AD and in reducing the financial load on both patients and caretakers (Bhatti et al., 2020).

Isolated from the leaves of Garcinia cowa, chamuangone contains active constituents that exhibit various pharmacological activities. Literature showed that extraction of chamuangone was carried out by utilizing n-Hexane; however, alternative green solvents, such as vegetable oils (e.g. rice bran oil), are used to obtain higher yield (Sae-Lim et al., 2019a). Isolated chemicals and extracts derived from different portions of G. cowa have revealed interesting bioactivities, such as antioxidant, cytotoxic, antibacterial, antimalarial, anti-inflammatory, and antimicrobial properties.

Mice were used to create a 42-day AD model by subcutaneously delivering D-galactose to animals to trigger the disease and to study the possible anti-AD properties of CRBO. One of the main neurotoxins, aluminium chloride, causes buildup in brain mitochondrial malfunctioning and dramatically accelerates the mutation of DNA and proteins and ROS. The fundamental cause of AD, which destroys neurons by escalating oxidative stress, is the extended and substantial exposure to aluminium (chloride) toxicity. This oxidative pressure modified cellular working, subdued antioxidant defense system, and produced structural defect to functional proteins that led to AD (Yin et al., 2020).

Low-dose D-galactose intervention over an extended period of time led to abnormalities that resembled natural aging processes in animals, including oxidative stress, cognitive impairment, a weakened immune system, and changes in gene transcription. Mice exposed to D-galactose over an extended period also developed neurotoxicity, and was utilized as a model to examine the mechanism of AD. Aluminum and d-galactose imitating cognitive deficits and diseases similar to AD served as useful models for researching AD treatments (Mahdi et al., 2021). With the modification of behavioral and biochemical indicators, in the current study, aluminum chloride- and D-galactose-induced memory impairment was alleviated by CRBO (Kamel et al., 2018). By interacting with the central nervous system’s (CNS) AchE enzyme, aluminum chloride and D-galactose led to ongoing stress that impaired cognition (Xing et al., 2018). Because of the extra release of ROS, the body was unable to eliminate it, resulting in oxidative stress. Biochemical studies were conducted to assess endogenous antioxidant capacity (Mantzavinos and Alexiou, 2017). By regulating both motor and non-motor dysfunctions, CRBO and rivastigmine were compared in this study. The behavioral and physiological alterations brought on by aluminium chloride and D-galactose were lessened by CRBO (Saleem et al., 2022). CRBO restored both behavioral and metabolic alterations in AD model.

The current study explained the neuroprotective effects of CRBO, as administration of aluminium chloride and D-galactose caused cognitive behavioral alteration coupled with locomotor impairments (Singh et al., 2018). To evaluate locomotor and exploratory activities, the open field test entailed exploring both center and periphery squares. While the disease control group showed reduced exploration, all CRBO-treated groups and rivastigmine-treated group showed improvement in square crossing (Ahmadi et al., 2017). Evaluation of hippocampus-dependent memory and spatial learning was caused using the Morris water maze test (Sharma et al., 2019). Animals’ persistent cognition and capacity to use alternative arms was measured by using the Y-maze test; these were decreased in mice receiving chronic AD induction agents (Lu et al., 2020). The transfer latency of elevated maze test was decreased in retention phase on day 42 in the animals of acquisition trial conducted on day 41. CRBO treatment groups displayed decreased transfer latency compared to the disease control animals and showed effects that lessened dementia as well as cognition (Pairojana et al., 2021). The results showed that CRBO and rivastigmine reduced memory and retention impairments generated by aluminum chloride and D-galactose.

Lipid peroxidation is an intricate procedure connecting the conjugation of oxidative radicals with polyunsaturated fats, producing a range of extremely reactive conductive aldehydes (Reed, 2011). One of the primary targets of the lipid peroxidation process is the CNS (Sultana et al., 2013). AD patients have increased polyunsaturated fatty acid (PUFA) oxidation, impaired antioxidant defense, more oxygen intake, and oxidative stress in their cortex with regional variations in the mitochondria (Ansari and Scheff, 2010). A strong correlation between
free-radical-induced injury and the disease’s neuropathology is demonstrated by assessing the activity of antioxidant enzymes and their co-localization to senile plaques and dystrophic neurites. It has been demonstrated that a lack of GSH may contribute to a variety of human disorders (Zhang et al., 2023). GSH levels showed a decrease in AD groups but increase in treatment groups.

Catalase is a crucial enzyme and uncharged of eliminating hydrogen peroxide by its breakdown hence preserving the optimum amount of the compound in the cell, which is for normal signaling activities. Catalase deficiency has been linked to many age-related degenerative disorders, including AD (Nandi et al., 2019). The catalase level was evaluated via the superior and middle temporal gyri, as well as AD hippocampus, which showed elevation compared to the disease control group (Lovell et al., 1995; Padurariu et al., 2010). All cells produce ROS from biochemical and molecular pathways, such as superoxide and hydrogen peroxide. These ROS have potential to disrupt oxidatively membrane lipids, proteins, and DNA if their levels are not regulated. An internal antioxidant enzyme called glutathione peroxidase-1 (GPx-1) converts hydrogen peroxide enzymatically to water to mitigate its adverse effects. Thus, GPx-1 controls these processes by reducing the buildup of hydrogen peroxide (Lubos et al., 2011).

Superoxide dismutase is a unique anti-oxidant enzyme that eliminates anion superoxide by converting it to hydrogen and oxygen peroxide, preventing the formation of peroxynitrite (a reactive oxidant), which causes additional damage (Rudan et al., 2015). Multiple AD characteristics have been linked to decreased levels of SOD, such as acceleration of plaque deposition and increased tau phosphorylation. Memory impairment and buildup of amyloid plaque are two pathogenic processes in AD that are significantly lowered by mitochondrial superoxide. Both GPx and SOD catalyse eliminate hydrogen peroxide, which produces harmful hydroxyl radicals. CRBO showed a remarkable increase in GPx and SOD levels in a dose-dependent manner.

Another indicator of oxidative damage is MDA which interacts with functional groups of protein molecules, lipoproteins, DNA, and RNA because it is a highly reactive dialdehyde generated following the decomposition of peroxidized PUFAs. MDA is potentially dangerous because it can cross-link proteins and induce mutagenesis. It was previously linked in the development of various neurodegenerative illnesses, aging, diabetes mellitus, and brain ischemia (Landau et al., 2013). The levels of MDA were higher in the disease control group and low in the treatment groups. Assessment of MDA levels is a very widely used method for determining lipid peroxidation.

Neurotransmitters, such as dopamine, noradrenaline, and serotonon, showed marked elevation in treatment groups whereas the disease control groups exhibited a decline in the levels of these neurotransmitters. AchE, a neurotransmitter, is revealed by parasympathetic neurons, plays a role in transducing signals that have an impact on recalling and learning. Cholinergic neurons are widely distributed in human brain. AchE affects neural systems like the amygdala, striatum, and hippocampus and is essential for memory improvement. AchE signaling is essential for cognitive functioning and control of inflammation. AD patients frequently exhibit AchE depletion and cholinergic signal transduction damage (Chen et al., 2022). Because oxidative stress impairs adenosine triphosphate (ATP) and acetyl formation, which in turn increases cholinesterase activity and decreases AchE activity in the hippocampus, animals given D-galactose may experience cholinergic deficits. The disease control group receiving aluminum chloride and D-galactose demonstrated a noticeably elevated level of AchE. CRBO- and rivastigmine-treated animals, however, displayed a subsequent drop in AchE levels, supporting the anti-Alzheimer’s activity of CRBO (Saleem et al., 2022). Examination of brain tissue samples using histopathology revealed that treatment with CRBO significantly improved the formation of NFTs, vacuolization, and senile plaques in the brain, which are hallmark features of AD. However, the disease control group showed no significant changes in the histology of vital organs, except for some degree of vascular congestion in the heart, parenchymal congestion in the kidney, and hepatic fibrosis. However, treatment with CRBO reversed these changes, indicating a potential therapeutic effect on AD-related pathology.

**Conclusions**

The conclusion demonstrates a complete assortment of biochemical analysis—reduced AchE activity, increased GSH levels, and heightened CAT. Free radical-eliminating and anti-inflammatory activities of CRBO demonstrate its neuroprotective impact in D-galactose- and aluminum chloride-induced AD neuroinflammation and memory impairment. These results underscore the nanocarriers’ ability to modulate neurotransmitter levels and counteract oxidative stress, reaffirming their potential as a promising therapeutic tool. Furthermore, our histological analysis of hippocampal regions reinforces the protective properties of CRBO. This protective effect is notably conspicuous when compared to the disease control group, showcasing the preservation of neuronal integrity, a reduction in dark neurons, and a decrease in
pathological features within the treated groups. These findings highlight the substantial promise of CRBO in safeguarding brain health and mitigating neurodegenerative processes. The findings offer novel information that highlights CRBO as a viable therapy for diseases with neurodegenerative etiologies. However, further investigation is required to clarify the precise molecular foundation of AD treatment.

Author Contributions

Uzma Saleem, Muhammad Ajmal Shah, Pharkphoom Panichayupakaranant, and Ana Sanches Silva conceived and designed the research. Badriyah S. Alotaibi, Sadaf Waseem, Zunera Chaudhary, and Maryam Farrukh performed the experiments. Ifat Alsharif, Wedad Saeed Alqahtani, Abdullah R. Alanzi, Mona N. BinMowyna, Yasmene F. Alanazi, Abdulrahman M. Almuwallad, Abdulmujid M. Almuwallad, and Khairul Anam analyzed and interpreted the data. All authors contributed equally to the preparation, revision, and final approval of the manuscript for submission.

Conflicts of Interest

The authors declared no conflict of interest.

Data Availability Statement

Original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.

Acknowledgments

Authors gratefully acknowledge the Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2024R73), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Authors extend their appreciation to researchers supporting project number (RSPD2024R885) at King Saud University Riyadh Saudi Arabia for supporting this research. Thanks to Universitas Diponegoro, Indonesia, through Adjunct Professor, World-Class University Program 2024. Ana Sanches Silva thanks FCT/MCTES for funding (UIDB/00211/2020).

References


Vorhees, C.V. and Williams, M.T. 2006. Morris water maze: procedures for assessing spatial and related forms of learning and
Chamuangone-rich rice bran oil for treating neurodegenerative disorders


### Supplementary

#### Table S1. Tabular Data.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>Disease control</th>
<th>Standard 2.5 mg/kg</th>
<th>Standard 5.0 mg/kg</th>
<th>Standard 7.5 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of square crossing (Figure 1)</td>
<td>52.0 ± 0.57</td>
<td>15 ± 0.68***</td>
<td>48 ± 0.69***</td>
<td>24 ± 0.76***</td>
<td>35.0 ± 0.75***</td>
</tr>
<tr>
<td>Peripheral exploration numbers (Figure 2)</td>
<td>143 ± 0.50</td>
<td>43 ± 0.65***</td>
<td>102 ± 0.57***</td>
<td>56 ± 0.69***</td>
<td>68 ± 0.67***</td>
</tr>
<tr>
<td>Central exploration numbers (Figure 3)</td>
<td>99 ± 0.55</td>
<td>35 ± 0.73***</td>
<td>101 ± 0.72***</td>
<td>52 ± 0.53***</td>
<td>64 ± 0.79***</td>
</tr>
<tr>
<td>Morris water maze test/escape latency (Figure 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 39</td>
<td>40 ± 0.71</td>
<td>58 ± 0.75***</td>
<td>57 ± 0.72***</td>
<td>59 ± 0.57***</td>
<td>56 ± 0.65***</td>
</tr>
<tr>
<td>Day 40</td>
<td>39 ± 0.69</td>
<td>51 ± 0.67***</td>
<td>46 ± 0.63ns</td>
<td>48 ± 0.58***</td>
<td>49 ± 0.57***</td>
</tr>
<tr>
<td>Day 41</td>
<td>35 ± 0.57</td>
<td>31 ± 0.71***</td>
<td>37 ± 0.67 ns</td>
<td>37 ± 0.61***</td>
<td>34 ± 0.69***</td>
</tr>
<tr>
<td>Day 42</td>
<td>20 ± 0.66</td>
<td>28 ± 0.57***</td>
<td>19 ± 0.53***</td>
<td>25 ± 0.54 ns</td>
<td>22 ± 0.57***</td>
</tr>
<tr>
<td>Y-maze task</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of triads (Figure 5)</td>
<td>8 ± 0.57</td>
<td>2 ± 0.59***</td>
<td>6 ± 0.56***</td>
<td>3 ± 0.57*</td>
<td>4 ± 0.59*</td>
</tr>
<tr>
<td>Number of arm entries (Figure 6)</td>
<td>70 ± 0.52</td>
<td>15 ± 0.70***</td>
<td>65 ± 0.75***</td>
<td>20 ± 0.75***</td>
<td>30 ± 0.61***</td>
</tr>
<tr>
<td>Spontaneous alterations (%) (Figure 7)</td>
<td>11 ± 0.53</td>
<td>2 ± 0.77***</td>
<td>9 ± 0.56***</td>
<td>5 ± 0.60***</td>
<td>8 ± 0.58*</td>
</tr>
<tr>
<td>Elevated maze test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transfer latency (Figure 8)</td>
<td>24 ± 0.67</td>
<td>74 ± 0.76***</td>
<td>34 ± 0.73***</td>
<td>78 ± 0.87***</td>
<td>62 ± 0.67***</td>
</tr>
</tbody>
</table>

*P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant.